Demand for Non-Alcoholic Steatohepatitis Clinical Trials in Japan

Future Market Insights

Key Insight

The demand for non-alcoholic steatohepatitis clinical trials in Japan is projected to grow from USD 161.6 million in 2025 to USD 269.6 million by 2035, at a CAGR of 5.3%. Interventional will dominate with a 45.4% market share, while phase 3 will lead the phase segment with a 40.0% share.

December 12, 2025

Anurag Sharma

250 Pages

Cite this Report

Demand for Non-Alcoholic Steatohepatitis Clinical Trials in Japan

https://www.futuremarketinsights.com/reports/japan-non-alcoholic-steatohepatitis-clinical-trials-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

The Vanguard Group
F. Hoffmann-La Roche Ag
ICON plc
Novartis

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Demand for Non-Alcoholic Steatohepatitis Clinical Trials in Japan

Key Players

Similar Industry Reports